PHVS Live signals | Maximize Profits with Getagraph.com

BUY 104876 min ago

@ $28.00

Issued: 13 Feb 2024 @ 09:35

Return: -18.68%

Previous signal: Feb 12 - 11:18

Previous signal: Sell

Return: -7.41 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	82 107.00
Average Volume	91 551.00
Market Cap	1.23B
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.600 ) 2024-06-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.13
ATR14	$0.336 (1.47%)

Volume Correlation

Long: 0.04 (neutral)

Short: -0.40 (neutral)

Signal:(48.781) Neutral

Pharvaris N.V. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharvaris N.V. Correlation - Currency/Commodity

0.52
( weak )

0.53
( weak )

-0.55
( weak negative )

0.39
( neutral )

-0.14
( neutral )

-0.09
( neutral )

Pharvaris N.V. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-252 271 (0.00 %)
EPS:	$-2.57

FY	2023
Revenue:	$0
Gross Profit:	$-252 271 (0.00 %)
EPS:	$-2.57

FY	2022
Revenue:	$0
Gross Profit:	$-150 186 (0.00 %)
EPS:	$-2.27

Financial Reports:

No articles found.

Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.